Maze Therapeutics (MAZE) director granted 18,000 options at $23.67

Maze Therapeutics director Neil Exter was granted a stock option to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) at an exercise price of $23.67 per share.

Rhea-AI Filing Summary

Maze Therapeutics director Neil Exter was granted a stock option to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) at an exercise price of $23.67 per share. The option was granted on 09/22/2025, is exercisable beginning 09/21/2025, and expires 09/21/2035. The award vests in nine equal monthly tranches (1/9 each) with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.

Positive

• Grant disclosed promptly: Form 4 filed and signed within two days of the reported transaction (09/22/2025 grant; 09/24/2025 signature).
• Clear vesting schedule: Option vests as to 1/9 monthly with first tranche on 10/01/2025, providing transparent service conditions.

Negative

• Potential dilution noted: Grant represents the right to acquire 18,000 shares, which may dilute existing shareholders when exercised.
• Limited context on aggregate holdings: Filing does not state the reporting person's total pre-existing beneficial ownership beyond this option.

Insights

Corporate Compensation Analyst

TL;DR: Director received a standard long-term incentive: a 10-year option for 18,000 shares at $23.67 with nine-month staged vesting starting Oct 1, 2025.

This award appears structured as a retention and alignment tool tying the directors interests to long-term equity performance. The exercise price equals the stated price in the filing and the ten-year term is typical for option grants. Vesting in nine monthly tranches after grant implies a short-term phased service requirement rather than front-loaded immediate vesting. The disclosure is complete for a Form 4: grant size, price, exercisability, vesting schedule, and expiration are all stated.

Securities Governance Specialist

TL;DR: Filing documents a routine director option grant with clear terms and proper Section 16 reporting within two days of grant.

The Form 4 shows timely reporting and includes necessary mechanics: grant date, exercise price, number of underlying shares, exercisable and expiration dates, and a vesting explanation. No indication of amendments, derivative complexities, or indirect holdings beyond a direct ownership entry. For governance review, the filing supplies the required facts but does not disclose board approval context or aggregate holdings outside this transaction.

Insider Trade Summary

Grant/Award: 18,000 shares

Grant/Award 1 txn

Insider Exter Neil

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 contracts (Direct)

Footnotes (1)

1. F1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option did Neil Exter receive according to the MAZE Form 4?

He received a stock option to purchase 18,000 shares of MAZE at an exercise price of $23.67 per share.

When does the option vest and become exercisable?

The option vests in nine equal monthly tranches (1/9 each) with the first tranche vesting on October 1, 2025; the filing shows exercisability beginning 09/21/2025.

What is the options expiration date?

The option expires on 09/21/2035.

When was the Form 4 filed and who signed it?

The Form 4 includes a signature by Courtney Phillips, as attorney-in-fact, dated 09/24/2025.

Does the filing indicate indirect ownership or other holdings?

No; the filing lists the holding as Direct (D) for the 18,000-option shares and does not disclose other aggregate holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/24/2025 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Exter Neil

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.67	09/22/2025		A		18,000		(1)	09/21/2035	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.